A better understanding of the exact mechanisms of the “switching” processes between apoptosis and autophagy through PI3K and Raf inhibitor usage in the context of the Bcl-2:beclin-1 complex formation opens up new perspectives in the fight against gliomas, both in the context of designing new therapies and exploring their resistance to elimination through programmed death. The gene discussed is BECN1; the disease is glioma.